Mark Baxter

And they're all looking at it in a slightly different way.

So for Oregon and Colorado, for instance, people can access those treatment centers.

But in Oregon, as an example, it's not people who have chronic mental health conditions.

It's people who might need help with a life transition or mild depression or prolonged grief or some other challenge.

Whereas in Australia, we're really targeting people with severe and persistent mental health conditions, so treatment-resistant depression.

or PTSD that's been around for quite a while for someone and they've tried lots of different things before.

So the people we're seeing have quite a complex or enduring mental health condition and they've often tried many, many things over many years.

So by the time they get to us, they feel like they've exhausted different treatments.

And we're seeing a lot of what they call comorbidities.

So it's not just PTSD.

There might be anorexia that comes with that, or there might be depression and OCD.

So people are coming with not just one kind of mental health condition.

It's often a mixture.

Yeah, the important thing to say, and we have a hard time having this stick with people, which is it's psychedelic-assisted therapy.

Now, what we're doing is we're combining psychotherapy with a particular compound that has certain properties, and I'll talk about the difference in the properties.

That can create a non-ordinary state of experience that can allow us to work with a person in a way that we couldn't do in a regular therapy setting with ordinary state consciousness.

So we're shifting someone's state of consciousness so that we can make therapy more powerful.

So the drug itself is not what we're kind of really focused on.

People get fascinated about the drugs and what do they do in the brain?

How are they doing this?